CHEMICAL AND GLUTATHIONE CONJUGATION-RELATED DEGRADATION OF FOTEMUSTINE - FORMATION AND CHARACTERIZATION OF A GLUTATHIONE CONJUGATE OF DIETHYL (1-ISOCYANATOETHYL) PHOSPHONATE, A REACTIVE METABOLITE OF FOTEMUSTINE

被引:8
作者
BRAKENHOFF, JPG
COMMANDEUR, JNM
DEKANTER, FJJ
VANBAAR, BLM
LUIJTEN, WCMM
VERMEULEN, NPE
机构
[1] FREE UNIV AMSTERDAM,LEIDEN AMSTERDAM CTR DRUG RES,DIV MOLEC TOXICOL,1081 HV AMSTERDAM,NETHERLANDS
[2] FREE UNIV AMSTERDAM,DEPT ORGAN CHEM,1081 HV AMSTERDAM,NETHERLANDS
[3] TECHNOL SERVIER,F-45000 ORLEANS,FRANCE
关键词
D O I
10.1021/tx00039a016
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fotemustine is a chemotherapeutic drug for the treatment of melanoma. In this study, we investigated the metabolic and chemical stability of fotemustine with P-31-NMR and FAB-MS. In the absence of GSH, 95% of fotemustine decomposed rapidly into a reactive diethyl ethylphosphonate (DEP) isocyanate, both in rat liver S-9 fraction and in HEPES buffer (pH = 7.4). DEP-isocyanate in turn hydrolyzed rapidly into diethyl (1-aminoethyl)phosphonate, which reacted subsequently with the parent DEP-isocyanate. The remaining 5% of fotemustine was shown to decompose via dechlorination into diethyl [1-(3-nitroso-2-oxoimidazolidin-1-yl)ethyl]-phosphonate. In the presence of GSH, hydrolysis of DEP-isocyanate was blocked, and a glutathione conjugate (DEP-SG) was formed instead. DEP-SG was relatively stable at 37 degrees C in HEPES buffer. Only two minor and as yet unidentified decomposition products were formed. Addition of N-acetyl-L-cysteine (NAC) to DEP-SG in HEPES buffer converted DEP-SG rapidly into the corresponding NAC conjugate of DEP-isocyanate (DEP-NAC). The formation of DEP-SG from DEP-isocyanate and GSH appeared to be spontaneous. The extent of formation of DEP-SG from fotemustine and GSH was equal in both enzymatically active and inactive rat liver S-9 fractions. In the presence and in the absence of GSH, the half-lives of decomposition (t(1/2)) of fotemustine were 33 +/- 6 and 27 +/- 3 min, respectively. The formation of the DEP-isocyanate and 2-chloroethanediazohydroxide intermediates from fotemustine appeared to be rate limiting, and not the hydrolysis of the DEP-isocyanate nor its conjugation to GSH. Active or inactive rat liver Ss fractions accelerated the decomposition of fotemustine slightly; i.e., the t(1/2) of fotemustine decreased from 39 +/- 3 to 29 +/- 1 min. Further knowledge of the metabolic and chemical stability of fotemustine and DEP-isocyanate will contribute to a better understanding of fotemustine-related cytostatic effects and toxic side effects and to the design of chemoprotection against undesired toxic side effects.
引用
收藏
页码:380 / 389
页数:10
相关论文
共 54 条
[1]   ACTIVE-SITE SPECIFIC INACTIVATION OF CHYMOTRYPSIN BY CYCLOHEXYL ISOCYANATE FORMED DURING DEGRADATION OF CARCINOSTATIC 1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA [J].
BABSON, JR ;
REED, DJ ;
SINKEY, MA .
BIOCHEMISTRY, 1977, 16 (08) :1584-1589
[2]  
BABSON JR, 1978, BIOCH BIPHYS RES COM, V60, P515
[3]   GLUTATHIONE - A VEHICLE FOR THE TRANSPORT OF CHEMICALLY REACTIVE METABOLITES INVIVO [J].
BAILLIE, TA ;
SLATTER, JG .
ACCOUNTS OF CHEMICAL RESEARCH, 1991, 24 (09) :264-270
[4]   PHARMACOKINETIC PROFILE OF FOTEMUSTINE IN RAT PLASMA BY ELECTROCHEMICAL DETECTION [J].
BARTOSEK, I ;
CORADA, M ;
DALLARDA, S ;
LUCAS, C ;
DELOFFRE, P ;
GUAITANI, A .
XENOBIOTICA, 1991, 21 (02) :235-242
[5]  
BERMEULEN NPE, 1993, PERSPECTIVES MED CHE, P573
[6]   BICARBONATE-CATALYZED HYDROLYSIS OF HEXAMETHYLENE DIISOCYANATE TO 1,6-DIAMINOHEXANE [J].
BERODE, M ;
TESTA, B ;
SAVOLAINEN, H .
TOXICOLOGY LETTERS, 1991, 56 (1-2) :173-178
[7]   INVIVO BINDING OF [1-C-14] METHYLISOCYANATE TO VARIOUS TISSUE PROTEINS [J].
BHATTACHARYA, BK ;
SHARMA, K ;
JAISWAL, DK .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (12) :2489-2493
[8]  
BIZZARI JP, 1988, B CANCER, V75, P813
[9]   IDENTIFICATION AND QUANTITATIVE-DETERMINATION OF GLUTATHIONE-RELATED URINARY METABOLITES OF FOTEMUSTINE, A NEW ANTICANCER AGENT [J].
BRAKENHOFF, JPG ;
COMMANDEUR, JNM ;
LAMOREE, MH ;
DUBELAAR, AC ;
VANBAAR, BLM ;
LUCAS, C ;
VERMEULEN, NPE .
XENOBIOTICA, 1993, 23 (08) :935-947
[10]  
BROWN GL, 1986, J EXP MED, V163, P1319